INS and obesity disorder: Recent reviews highlight that liposomal formulations designed for metabolic applications—such as the encapsulation of insulin sensitizers [54] lipid-lowering agents [57,140], or anti-obesity compounds [63]—remain almost entirely within the preclinical research stage, with very few candidates advancing toward clinical evaluation.